• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

NICE Delays Drug Appraisal Fee Plan


January 19, 2017

The UK’s National Institute of Health and Care Excellence (NICE) announced this week that its plans to charge companies for its appraisals of drugs, medical devices and diagnostics have been put on hold until the UK’s new government completes its life sciences strategy, the Regulatory Affairs Professionals Society (RAPS) reports.

NICE's plan to charge for appraisals, proposed in October 2016, would see companies pay fees of up to £282,000 ($347,700) for each cost-effectiveness assessment. 

NICE’s chief executive, Sir Andrew Dillon, said in a statement: “We have been working to create a new funding model for technology evaluation to meet the government’s challenge to drive efficiency and deliver better value. We’ve agreed with the Department of Health to wait for the Government’s life sciences strategy to be completed before we move forward with our plans.” 

See more at: http://www.raps.org/Regulatory-Focus/News/2017/01/16/26612/NICE-Halts-Plans-to-Charge-for-Appraisals/#sthash.QMhLynIB.dpuf

Related Videos
Related Content